Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice (SFPRT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04049188 |
Recruitment Status :
Recruiting
First Posted : August 8, 2019
Last Update Posted : January 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer Metastatic | Radiation: Single-Fraction Palliative Radiation Therapy | Not Applicable |
Hospice care for terminally ill patients with metastatic cancer improves quality of life, pain control, and potentially also survival when patients are enrolled early.1-3 However, hospice programs are often seen by patients and their caregivers as the last resort after exhaustion of all effective treatment options. The need to revoke active treatment (for all hospice patients with cancer outside of the VA system) discourages hospice enrollment.
This study aims to understand and analyze barriers to access specifically for short course palliative radiation therapy in cancer patients enrolled in hospice.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 31 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Impact of Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice |
Actual Study Start Date : | January 1, 2020 |
Estimated Primary Completion Date : | January 1, 2021 |
Estimated Study Completion Date : | December 31, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Single-Fraction Palliative RT
Single-Fraction Palliative Radiation Therapy Adminstration
|
Radiation: Single-Fraction Palliative Radiation Therapy
All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain. |
- Change in Opioid Use for Pain Management [ Time Frame: Through study completion, an average of 1 year ]Opioid Dosage (mg/day)
- Improved Quality of Life Measures [ Time Frame: During study completion ]Questionnaires using Herth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale
- Improved Activities of Daily Living [ Time Frame: During study completion ]Questionnaires using Hearth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Solid Tumor Malignancies and Multiple Myeloma with Bone Metastases and Associated Bone Pain Enrolled in Hospice
Exclusion Criteria:
- Decisionally-Impaired Subjects, Pregnant Women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04049188
Contact: Andy Kyler, BSN, MBA | 5036192621 | andy.kyler@carepartners.org | |
Contact: Christa Nicholas | 5036469565 | Christa.Nicholas@carepartnersor.org |
United States, Oregon | |
CarePartners | Recruiting |
Hillsboro, Oregon, United States, 97006 | |
Contact: Christa Nicholas 503-648-9565 | |
Principal Investigator: Andy Kyler, BSN, MBA |
Responsible Party: | Care Partners |
ClinicalTrials.gov Identifier: | NCT04049188 |
Other Study ID Numbers: |
00019460 20181015 ( Other Grant/Funding Number: Knight Cancer Institute - Community Partnership Program ) |
First Posted: | August 8, 2019 Key Record Dates |
Last Update Posted: | January 23, 2020 |
Last Verified: | January 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cancer Patients Hospice Care Palliative Radiation Therapy |